ClinicalTrials.gg

Program

Minoxidil

Also written as “Minoxidil Tablets”, “minoxidil + finasteride” and “Minoxidil oral solution”.

Its studies are mostly in Alopecia · Hypotrichosis, led by 9 companies.

Furthest: phase 3, since May 8, 202313 company-led studies, 4 open or runningNext primary completion: Dec 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aneira Pharma21 open or runningphase 1since May 8, 2023Mar 17, 2023none ahead
Galderma Group20 open or runningno phasesince May 29, 2015May 29, 2015none ahead
Industrial Farmacéutica Cantabria21 open or runningphase 3since May 25, 2023May 25, 2023none ahead
Johnson & Johnson20 open or runningphase 3since Sep 8, 2005Sep 8, 2005none ahead
3SBio11 open or runningphase 3since Jul 15, 2025Jul 15, 2025Dec 2027phase 3 · NCT07080931
Beijing Dayspring Pharmaceutical Technology10 open or runningphase 2since Jul 1, 2025Jul 1, 2025none ahead
Eurofarma Laboratorios11 open or runningphase 3since Apr 8, 2026Apr 8, 2026Oct 30, 2028phase 3 · NCT07529977
Maja Kovacevic, MD10 open or runningno phasesince Jun 25, 2015Jun 25, 2015none ahead
Samson Clinical Operations Pty10 open or runningphase 3since Apr 6, 2025Apr 6, 2025none ahead

Also a collaborator on its studies: bioskin-gmbh and astrum-cro-s-l.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 8, 2005First study: phase 3 study in AlopeciaNew to Johnson & JohnsonJohnson & Johnson · NCT00151515 · 352 enrolled · United States
  2. Jun 15, 2010Phase 3 study in AlopeciaJohnson & Johnson · NCT01145625 · 322 enrolled · United States, Canada, France and more
  3. May 29, 2015Galderma Group's first studies: 2 no phase studies in AlopeciaNew to Galderma GroupGalderma Group · NCT02460497, NCT02460289
  4. Jun 25, 2015Maja Kovacevic, MD's first study: no phase study in AlopeciaNew to Maja Kovacevic, MDMaja Kovacevic, MD · NCT02486848 · Italy
  5. Mar 17, 2023Aneira Pharma's first study: early phase 1 study in HypotrichosisNew to Aneira PharmaAneira Pharma · NCT05790941 · 12 enrolled · United States
  6. May 8, 2023Phase 1 study in AlopeciaAneira Pharma · NCT05864885 · 14 planned
  7. May 25, 2023Industrial Farmacéutica Cantabria's first study: phase 3 study in AlopeciaNew to Industrial Farmacéutica CantabriaIndustrial Farmacéutica Cantabria · NCT05888922 · 520 enrolled · Germany, Italy, Portugal and more
  8. May 31, 2023Phase 1 study in HealthyIndustrial Farmacéutica Cantabria · NCT06015516 · 14 enrolled · Spain
  9. Apr 6, 2025Samson Clinical Operations Pty's first study: phase 3 study in AlopeciaNew to Samson Clinical Operations PtySamson Clinical Operations Pty · NCT06924632 · 142 enrolled · Australia
  10. Jul 1, 2025Beijing Dayspring Pharmaceutical Technology's first study: phase 2 study in AlopeciaNew to Beijing Dayspring Pharmaceutical TechnologyBeijing Dayspring Pharmaceutical Technology · NCT07076706 · 110 enrolled · China
  11. Jul 15, 20253SBio's first study: phase 3 study in AlopeciaNew to 3SBio3SBio · NCT07080931 · 294 planned · China
  12. Apr 8, 2026Eurofarma Laboratorios's first study: phase 3 study in AlopeciaNew to Eurofarma LaboratoriosEurofarma Laboratorios · NCT07529977 · 372 planned · Brazil

Ahead

  1. Dec 2027Primary completion: phase 3 study in Alopecia3SBio · NCT07080931
  2. Oct 30, 2028Primary completion: phase 3 study in AlopeciaEurofarma Laboratorios · NCT07529977

TargetBeta

“Sulfonylurea receptor 2, Kir6.2 opener”ChEMBL 37, by rule

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07529977Alopecia · Brazil3Not yet recruitingEurofarma LaboratoriosOct 30, 2028372
NCT07080931Alopecia · China3Recruiting3SBioDec 2027294
NCT07076706Alopecia · China2CompletedBeijing Dayspring Pharmaceutical TechnologyAug 26, 2025110
NCT06924632Alopecia · Australia3CompletedSamson Clinical Operations PtyMay 15, 2026142
NCT06015516Healthy · Spain1CompletedIndustrial Farmacéutica CantabriaMar 8, 202414
NCT05888922Alopecia · Germany, Italy, Portugal and more3Active, not recruitingIndustrial Farmacéutica CantabriaOct 2026520
NCT05864885Alopecia1Not yet recruitingAneira PharmaJul 17, 202314
NCT05790941Hypotrichosis · United StatesEarly 1UNKNOWNAneira PharmaJun 30, 202312
NCT02486848Alopecia · Italy–WithdrawnMaja Kovacevic, MDDec 20160
NCT02460497Alopecia · United States–CompletedGalderma GroupSep 19, 201561
NCT02460289Alopecia · United States–CompletedGalderma GroupNov 201563
NCT01145625Alopecia · United States, Canada, France and more3CompletedJohnson & JohnsonFeb 2012322
NCT00151515Alopecia · United States3CompletedJohnson & JohnsonJul 2004352

How it is read

Names in the registry

  • “Minoxidil Tablets”, 2 entries
  • “Minoxidil”, 2 entries
  • “minoxidil + finasteride”, 2 entries
  • “Minoxidil oral solution”, 1 entry
  • “5% minoxidil foam”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.